Landgren, C. Ola http://orcid.org/0000-0001-6485-4839
Chari, Ajai
Cohen, Yael C. http://orcid.org/0000-0002-9061-7287
Spencer, Andrew
Voorhees, Peter
Estell, Jane A.
Sandhu, Irwindeep
Jenner, Matthew W.
Williams, Catherine
Cavo, Michele
van de Donk, Niels W. C. J.
Beksac, Meral
Moreau, Philippe
Goldschmidt, Hartmut
Kuppens, Steven
Bandekar, Rajesh
Clemens, Pamela L.
Neff, Tobias
Heuck, Christoph
Qi, Ming
Hofmeister, Craig C. http://orcid.org/0000-0003-4816-1607
Funding for this research was provided by:
Janssen Research and Development
Article History
Received: 22 February 2019
Revised: 5 December 2019
Accepted: 15 January 2020
First Online: 5 February 2020
Compliance with ethical standards
:
: COL received grant support from the National Institutes of Health, Food and Drug Administration, Multiple Myeloma Research Foundation, International Myeloma Foundation, Leukemia & Lymphoma Society, Perelman Family Foundation, Rising Tides Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, and Karyopharm; received honoraria from/served on advisory committees for Adaptive Biotechnologies Corp, Amgen, Bristol-Myers Squibb, Celgene, Cellectis, Glenmark, Janssen, Karyopharm, Merck, Pfizer, Takeda, and The Binding Site; and served on independent data monitoring committees for Takeda, Novartis, and Janssen. AC received research funding from Pharmacyclics and served as a consultant for, received research funding from, and served on advisory committees for Amgen, Array BioPharma, Celgene, Janssen, Millennium, Takeda, and Novartis. YCC received research funding from Amgen and Takeda; served on advisory boards for Janssen and Takeda; served on a speakers bureau for Amgen; and received travel grants from Janssen, Bristol-Myers Squibb, and Neopharm. AS received research funding and honoraria from Janssen. PV served as a consultant for Celgene, Janssen, Bristol-Myers Squibb, Novartis, Takeda, and Oncopeptides and is on speakers bureaus for Amgen, Celgene, and Janssen. JAE served on advisory committees for Janssen and Celgene. IS received honoraria from Janssen, Celgene, Takeda, Amgen, and Novartis. MWJ received honoraria from and served on speakers bureaus for Janssen, Celgene, Takeda, Amgen, and Novartis and served on advisory committees for Janssen, Celgene, Takeda, Amgen, Novartis, and Chugai. MC received honoraria from Janssen, Celgene, Amgen, Bristol-Myers Squibb, and Takeda. NWCJvdD received research funding from Janssen, Celgene, Bristol-Myers Squibb, Novartis, and Amgen. MB served on an advisory committee and a speakers bureau for Janssen, Amgen, Celgene, and Takeda. PM served on advisory committees for Celgene, Janssen, Takeda, Novartis, Amgen, and Roche. HG consulted for and received honoraria from Celgene, Janssen-Cilag, Novartis, Bristol-Myers Squibb, Chugai, and Art Tempi; served on speakers bureaus for Adaptive Biotechnologies, Celgene, Janssen-Cilag, Bristol-Myers Squibb, Amgen, and Takeda; received compensation for travel expenses from Celgene, Bristol-Myers Squibb, Janssen-Cilag, Chugai, Amgen, and Takeda; and received research funding from Bristol-Myers Squibb, Celgene, Chugai, Janssen-Cilag, Sanofi, Novartis, Takeda, Amgen, and Mundipharma. SK, RB, TN, and CH are employees of Janssen. PLC and MQ are employees of Janssen and hold equity in Johnson & Johnson. CCH is an investigator for trials conducted by Bristol-Myers Squibb, Oncolytics Biotech, Sanofi, Celgene, Janssen, Takeda, Kite, Juno, Karyopharm, GlaxoSmithKline, Novartis, Roche, AstraZeneca, Amgen, and Aduro Biotech; received institutional research funding from Celgene, Janssen, Takeda, Roche, Karyopharm, and Bristol-Myers Squibb; served on an advisory committee for Oncopeptides, Celgene, Adaptive Biotechnologies, and Thrasos Therapeutics; and received honoraria from AXIS Medical Education, PleXus Communications, priME Oncology, TRM Oncology, DAVA Oncology, American Society of Clinical Oncology, International Myeloma Foundation, Multiple Myeloma Research Foundation, Adaptive Biotechnologies, and Thrasos Therapeutics. CW has nothing to disclose. Janssen Research & Development LLC sponsored this trial, collaborated with the academic authors on its design, compiled and maintained the data, and agreed to publish this paper.